Louisiana State Employees Retirement System Purchases Shares of 14,600 Repligen Co. (NASDAQ:RGEN)

Louisiana State Employees Retirement System acquired a new position in Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 14,600 shares of the biotechnology company's stock, valued at approximately $2,625,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. lifted its stake in Repligen by 3.9% during the first quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company's stock worth $330,315,000 after purchasing an additional 65,550 shares during the period. State Street Corp grew its holdings in Repligen by 0.9% during the 2nd quarter. State Street Corp now owns 1,651,310 shares of the biotechnology company's stock worth $233,594,000 after acquiring an additional 14,647 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Repligen by 11.3% in the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company's stock worth $247,558,000 after acquiring an additional 157,807 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Repligen by 2.1% during the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company's stock worth $222,075,000 after purchasing an additional 29,215 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Repligen by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company's stock valued at $190,117,000 after buying an additional 137,220 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

RGEN traded down $2.22 on Tuesday, reaching $164.17. The company had a trading volume of 609,323 shares, compared to its average volume of 535,907. The company's fifty day moving average is $191.57 and its 200 day moving average is $173.25. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. The stock has a market cap of $9.17 billion, a P/E ratio of 228.02, a P/E/G ratio of 5.62 and a beta of 1.02. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts' consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. During the same quarter in the previous year, the firm earned $0.68 earnings per share. Repligen's revenue for the quarter was down 16.6% compared to the same quarter last year. As a group, analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RGEN. KeyCorp lifted their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. increased their price objective on Repligen from $170.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, December 20th. Finally, Stifel Nicolaus boosted their target price on Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $196.70.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the firm's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares of the company's stock, valued at $36,575,562.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of the company's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is currently owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.